INTRODUCTION {#S1}
============

Rare recessive diseases cause chronic diseases that often require hospitalization.^[@R1]^ For example, rare chronic kidney diseases (CKD) comprise the majority of cases treated within chronic dialysis and renal transplantation programs in the first 3 decades of life, but are notoriously difficult to diagnose.^[@R2]^ However, the genetic basis of approximately half of recessive diseases including CKD is still unknown (<http://omim.org/statistics/entries>). As recessive mutations represent directly the primary disease cause, gene identification offers a powerful approach to revealing disease mechanisms in such disorders. Furthermore, because recessive mutations predominantly convey loss of function, recessive single-gene defects can be transferred directly into animal models, to study the related disease mechanisms and to screen for small molecules as possible treatment modalities.

Nephronophthisis (NPHP) is a recessive cystic kidney disease that represents the most frequent genetic cause of CKD in the first three decades of life. NPHP-related ciliopathies (NPHP-RC) are typically recessive single-gene disorders that affect kidney, retina, brain and liver by prenatal-onset dysplasia or by organ degeneration and fibrosis in early adulthood.^[@R3]^ Ultrasonographically, NPHP are characterized by increased echogenicity and cyst formation at the corticomedullary junction in small or normal-sized kidneys ([Figure 1](#F1){ref-type="fig"}).^[@R4]^ And renal histology exhibits a characteristic triad of renal corticomedullary cysts, tubular basement membrane disruption, and tubulointerstitial inflitrations.^[@R5]^ Regarding renal, retinal and hepatic involvement there is phenotypic overlap of NPHP-RC with Bardet-Biedl syndrome (BBS).^[@R6]^ Identification of recessive mutations in 15 different genes (*NPHP1-NPHP15*)^[@R7]--[@R20]^ revealed that the encoded proteins share localization at the primary cilia-centrosomes complex, characterizing them as retinal-renal "ciliopathies".^[@R3],\ [@R21]^ However, the 15 known *NPHP-RC* genes explain less than 50% of all cases with NPHP-RC, indicating that many of the genetic causes of NPHP-RC are still elusive.^[@R22],\ [@R23]^

Some of the more recently identified genetic causes of NPHP-RC are exceedingly rare.^[@R15]^ This observation necessitates a strategy to identify additional genetic causes of NPHP-RC in *single* affected families. In this context whole exome capture with consecutive massively parallel sequencing, (here referred to as whole exome resequencing, WER), theoretically offers a powerful approach towards gene identification in rare recessive diseases.^[@R24]^ However, the utility of WER is hampered by the large number of genetic variants that result from whole exome sequencing in any given individual.^[@R18],\ [@R25]^

To overcome the difficulty of variant prioritization in WER, we developed a strategy that combines WER^[@R18]^ with homozygosity mapping.^[@R26]^ We here apply this approach to 10 families with siblings with the diagnosis of "NPHP-RC", based on clinical, renal sonographic, and/or histologic findings. Using this strategy we identified the primary causative mutations in 7 of the 10 sib pairs (70%). In six families we detect mutations of known *NPHP-RC* genes. In two additional families we revise the erroneous clinical diagnosis of NPHP-RC through identification of mutations in *SLC4A1* and *AGXT*. This established the correct diagnoses of distal renal tubular acidosis and hyperoxaluria, respectively, which had appeared as clinical phenocopies of NPHP-RC.

We hereby establish a non-invasive molecular genetic approach towards early detection and causation-based diagnosis of rare kidney diseases by applying WER and homozygosity mapping to sibling cases. The approach is efficient and can be extended to all rare recessive diseases, thereby facilitating the study of disease mechanisms.

RESULTS {#S2}
=======

Clinical features of sibs with an NPHP-RC phenotype {#S3}
---------------------------------------------------

From over 500 families with a diagnosis on NPHP-RC that were referred to us from worldwide sources for molecular genetic diagnosis we selected sibling cases with no known primary mutations from 10 different families ([Table 1](#T1){ref-type="table"}). Inclusion criteria were a diagnosis of NPHP-RC in both siblings based on renal ultrasonographic^[@R4]^ ([Figure 1](#F1){ref-type="fig"}) and/or histologic^[@R5]^ findings characteristic for NPHP or a related ciliopathy. Many cases had extrarenal symptoms typical for NPHP-RC, including retinitis pigmentosa and neurologic involvement ([Table 1](#T1){ref-type="table"}).

Homozygosity mapping in 10 sibs with a diagnosis of NPHP-RC {#S4}
-----------------------------------------------------------

The finding that most of the known *NPHP-RC* genes (*NPHP2-NPHP13*) contribute causative mutations in only a small number of cases each (\<1--3%)^[@R15]^ necessitates the ability to map and identify disease-causing genes in single families. We therefore employed a previously developed strategy,^[@R18],\ [@R26]^ that combines homozygosity mapping in single families with WER. We performed genome wide homozygosity mapping in the 10 sibships with NPHP-RC as described (see [Figure S1](#SD1){ref-type="supplementary-material"}).^[@R26]^ Eight families were known to be consanguineous and two had no evidence for consanguinity ([Table 1](#T1){ref-type="table"}). Homozygosity mapping yielded segments of likely homozygosity by descent ("homozygosity peaks")^[@R26]^ in all eight families with consanguinity, but in none of the two families (A2841 and F838) without consanguinity (see [Figure S1](#SD1){ref-type="supplementary-material"}). This is consistent with our previous finding that individuals with known consanguinity exhibit segments of homozygosity upon mapping, whereas segments of homozygosity are rare in outbred families.^[@R26]^ In the eight consanguineous families the number of homozygosity peaks ranged from one to fifteen ([Table 1](#T1){ref-type="table"} and [Figure S1](#SD1){ref-type="supplementary-material"}).

Mutations in six known NPHP-RC genes {#S5}
------------------------------------

Following homozygosity mapping and WER ([Figure S1 and Table S1--S2](#SD1){ref-type="supplementary-material"}), we identified recessive mutations in the known ciliopathy genes *INVS/NPHP2*, *NPHP4*, *BBS1*, *BBS9*, and *ALMS1* in five families with multiple affected sibs with NHPH-RC (families A2204, A2557, A2882, A2888, and A2841) respectively ([Table 1](#T1){ref-type="table"}, [Figure 2](#F2){ref-type="fig"} and [Table S1](#SD1){ref-type="supplementary-material"}). Individual A2557-21 with a homozygous truncating mutation in *NPHP4* had characteristic clinical signs ([Table 1](#T1){ref-type="table"}) and renal ultrasound features ([Figure 1a](#F1){ref-type="fig"}) of NPHP. Interestingly, individual A2557-31, who is a cousin of A2557-21 and has the same mutation, developed end-stage kidney disease (ESKD) at 32 years. This late manifestation with ESKD beyond age 25 years is unusual in NPHP. Individuals A2882-21 and -22, who both carry a mutation in *BBS1*, presented with postaxial polydactyly and obesity. Mutations in *ALMS1* cause Alström syndrome of which clinical features include blindness, obesity, type 2 diabetes, renal dysfunction, and hypertension. Individuals A2841-21 and -22, who have two truncating compound heterozygous mutations in *ALMS1*, presented with obesity, insulin resistance, retinitis pigmentosa and kidney enlargement which are consistent with the genetic findings.

Mutations in two known CKD genes phenocopy NPHP-RC {#S6}
--------------------------------------------------

Surprisingly, in families F650 and A3254 we identified mutations in the known CKD-causing genes *SLC4A1* and *AGXT1,* respectively, that apparently represent phenocopies of NPHP-RC ([Table 1](#T1){ref-type="table"}).First, renal biopsy performed in both male siblings of family F650 at 19 and 18 years of age, respectively, revealed the suspected diagnosis of NPHP-RC with cystic tubular ectasia ([Table 1](#T1){ref-type="table"}). This diagnosis was supported by the findings of polyuria, polydipsia, failure to thrive, coloboma of the eye, and metabolic acidosis, which was thought to be secondary to renal failure from NPHP. Subsequent renal ultrasound performed at 35 and 34 years of age, respectively, also showed features characteristic of NPHP, including increased echogenicity and corticomedullary cysts in kidneys of normal size ([Figure 1c](#F1){ref-type="fig"}). However, over the years both brothers developed requirement of oral bicarbonate supplementation of 3 g/day. They did not develop terminal renal failure by the ages of 35 and 34 years, respectively, and this late age of onset is not typical of NPHP. In addition, renal ultrasound showed increased echogenicity that was pronounced in the rims surrounding the corticomedullary renal cysts and in the pyramids ([Figure 1d](#F1){ref-type="fig"}), a feature unusual for NPHP. Identification of a homozygous mutation that deletes a highly conserved amino acid residue in *SLC4A1*, which encodes the anion exchange protein 1 (AE1), enabled us to make the unexpected diagnosis of distal renal tubular acidosis (dRTA) ([Table 1](#T1){ref-type="table"}, [Figure 2](#F2){ref-type="fig"} and [Table S1](#SD1){ref-type="supplementary-material"}). Recessive mutations of *SLC4A1* have been reported previously to cause dRTA with and without red blood cell dysmorphology.^[@R27]^

In another family with two affected cousins, A3254 and A3255, we suspected infantile-onset NPHP-RC ([Table 1](#T1){ref-type="table"}). Individual A3254 had end-stage kidney disease (ESKD) at three months with small echogenic kidneys on renal ultrasound ([Figure 1d](#F1){ref-type="fig"}). Individual A3255 developed ESKD at 3 months of age, had brain atrophy and developmental delay, and died age 19 months. Both cousins displayed retinal pigmentation ([Table 1](#T1){ref-type="table"}). WER revealed a homozygous mutation in *AGXT* which encodes alanine-glyoxylate transferase 1, thereby establishing the diagnosis of hyperoxaluria type 1 ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"} and [Table S1](#SD1){ref-type="supplementary-material"}).^[@R28]^ Thus, in both families, we established an accurate molecular diagnosis by WER, which was previously incorrectly ascribed to NPHP-RC early in the disease course, even following detailed evaluation by renal biopsy or ultrasound.

In family F93 with four children with NPHP-RC and typical renal ultrasonographic features ([Figure 1b](#F1){ref-type="fig"}), genetic mapping excluded the entire genome from linkage with a disease locus with the exception of the *PKHD1* locus ([Figure S1h](#SD1){ref-type="supplementary-material"}). Although no mutations were detected in *PKHD1* by WER, the mapping result implicates *PKHD1* as the most likely causative gene, which is known to cause autosomal recessive polycystic kidney disease (ARPKD). The four affected children of family F93 had a phenotype unusual for ARPKD, because the kidneys were not enlarged, and there was extrarenal involvement with retinal coloboma.

Finally, two additional families, F838 and A2059 were non-consanguineous ([Table 1](#T1){ref-type="table"}) and did not yield homozygosity peaks upon genetic mapping ([Figure S1i--j](#SD1){ref-type="supplementary-material"}). In family F838 for which both affected individuals had a renal ultrasound consistent with NPHP ([Figure 1e](#F1){ref-type="fig"}) we detected a heterozygous nonsense mutation in the ciliopathy gene *INPP5E* ([Table 1](#T1){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}), but we were unable to detect any additional mutations in trans at the same locus. Finally, we were unable to detect a likely primary causal locus in family A2059 ([Table 1](#T1){ref-type="table"} and [Table S1](#SD1){ref-type="supplementary-material"}). In addition, we examined variants in known ciliopathy genes in WER data of all 10 families. The included genes were *NPHP1*, *INVS*, *NPHP3*, *NPHP4*, *IQCB1*, *CEP290*, *GLIS2*, *RPGRIP1L*, *NEK8*, *SDCCAG8*, *TMEM67*, *TTC21B*, *WDR19*, *ZNF423*, *CEP164*, *BBS1*, *BBS2*, *ARL6*, *BBS4*, *BBS5*, *MKSS*, *TTC8*, *BBS9*, *BBS10*, *TRIM32*, *BBS12*, *MKS1*, *WDPCP*, *TMEM216*, *AHI1*, and *CCDC28B*. However, we could not detect any additional pathogenic variants in these genes in the seven solved and three unsolved cases. Furthermore, we checked genomic structural variants including large deletions and insertion, inversions, replacements, and translocations for the three unsolved cases based on WER, but there was no significant structural abnormality observed.

Taken together, we identified the disease-causing gene in 7 of 10 (70%) sibships, suggesting that homozygosity mapping with WER provides an efficient approach for molecular genetic diagnostics in diseases such as NPHP-RC and other ciliopathies where there is broad genetic locus heterogeneity.

DISCUSSION {#S7}
==========

Here, we demonstrate that WER, when combined with homozygosity mapping in sibling cases, represents a high-yield approach towards identification of primary causal mutations in rare recessive diseases. From our findings, we draw several conclusions: First, WER offers a viable, non-invasive approach for molecular diagnosis of rare recessive diseases. Second, however, to reduce the multitude of variants generated by WER, an *a priori* method to restrict this number is still required. Here, we show that the study of sib cases and the use of homozygosity mapping provides a robust solution to this problem. Third, using this approach, we achieved a high success rate for disease gene identification of 70%. In monogenic diseases about 85% of all recessive mutations are thought to reside within exons and adjacent intronic regions^[@R29]^ which are target regions of WER, so mutations in deep introns and promoter regions are not covered by WER. In addition, WER can miss a causal variant because of inadequate coverage (e.g. poor capture or poor sequencing) or inaccurate variant calling (e.g. a small but complex indel).^[@R30]^ Fourth, our study demonstrates that for individuals with childhood-onset renal failure, clinical diagnosis, renal ultrasound, and even renal histology represent relatively blunt diagnostic tools, which can be incapable of establishing the correct diagnosis. In this setting WER offers a powerful, non-invasive, cost-efficient diagnostic tool for arriving at a correct, unequivocal, etiology-based diagnosis.^[@R31]^ Fifth, rare, genetically heterogeneous chronic kidney diseases comprise the majority of cases of CKD in children but are notoriously difficult to diagnose. The use of WER will be beneficial for these individuals, because it will be possible to accurately assign them to therapeutic studies in larger cohorts. Sixth, our approach of combining homozygosity with WER can be applied to other rare recessive diseases. This may be of great clinical utility, as rare recessive disorders together cause a very high percentage of chronic diseases that require inpatient treatment in pediatrics. Finally, because WER reveals the major etiologic cause of a disease, gene identification will facilitate the elucidation of altered biological pathways, as well as the generation of animal models for testing of new treatment modalities.

WER now costs about \$1,000 each per sample from several providers due to the substantial cost reductions associated with next-generation sequencing technologies. It usually takes four to eight weeks to get WER data after samples are submitted. Then, another four to eight weeks are required to analyze the WER data including alignments, variant filtering, confirmation and segregation analysis by Sanger sequencing. Therefore, the overall process usually takes at least two to three months. This is only valid when analysis of WER is combined with HM. When mapping data are not available, more time is necessary for evaluation and there is no standard protocol to filter variants from WER. Many laboratories are using their own way to filter variants and are evaluating WER differently. Therefore, to use WER widely as a diagnostic tool, a standard analytic pipeline should be established.

MATERIALS AND METHODS {#S8}
=====================

Study Participants {#S9}
------------------

From worldwide sources we obtained blood samples, clinical and pedigree data following informed consent from individuals with NPHP-RC and/or their parents. Approval for human subjects' research was obtained from the University of Michigan Institutional Review Board and relevant local Review Boards. The diagnosis of NPHP-RC was made by (pediatric) nephrologists based on standardized clinical^[@R32],\ [@R33]^ and renal ultrasound^[@R4]^ criteria. Renal biopsies were evaluated by renal pathologists.^[@R5]^ Clinical data were obtained using a standardized questionnaire (<http://www.renalgenes.org>). The presence of retinal degeneration or neurologic involvement was evaluated by ophthalmologists and (pediatric) neurologists, respectively. In about 500 different families with NPHP-RC we excluded homozygous deletions of the *NPHP1* gene. In a subset of these families we excluded mutations in selected known *NPHP-RC* genes using an approach of high-throughput mutation analysis.^[@R34],\ [@R35]^ The remaining 10 families with multiple affected siblings without a molecular genetic diagnosis were entered into this study for homozygosity mapping and WER.

Homozygosity mapping {#S10}
--------------------

For genome-wide homozygosity mapping^[@R26]^ the 'Human Mapping 250k *Sty*I' array or the 'Genome-wide Human SNP 6.0 Array' from Affymetrix™ were utilized. Genomic DNA samples were hybridized, and scanned using the manufacturer's standard protocol at the University of Michigan Core Facility ([www.michiganmicroarray.com](http://www.michiganmicroarray.com)). Non-parametric LOD scores were calculated using a modified version of the program GENEHUNTER 2.1^[@R36],\ [@R37]^ through stepwise use of a sliding window with sets of 110 SNPs using the program ALLEGRO.^[@R38]^ Genetic regions of homozygosity by descent ('homozygosity peaks') were plotted across the genome as candidate regions for recessive genes (see [Figure S1](#SD1){ref-type="supplementary-material"}), as described.^[@R18],\ [@R39]^ Disease allele frequency was set at 0.0001, and Caucasian marker allele frequencies were used.

Whole exome resequencing (WER) {#S11}
------------------------------

Exome enrichment was conducted following the manufacturer's protocol for the 'NimbleGen™ SeqCap EZ Exome v2' beads (Roche NimbleGen Inc.). The kit interrogates a total of approximately 30,000 genes (\~330,000 CCDS exons). Massively parallel sequencing was performed largely as described in Bentley et al.^[@R40]^ For ten WER samples included in this study, the average of 118 million reads (100 bp) per each WER was obtained and the average coverage on target regions (exons) was 42.3 ± 13.4. For detail see [Online Methods in Supplementary Material](#SD1){ref-type="supplementary-material"}, available with the full text of this article at <http://www.nature.com/ki>.

Mutation calling {#S12}
----------------

Sequence reads were mapped to the human reference genome assembly (NCBI build 36/hg18) using CLC Genomics Workbench™ (version 4.7.2) software (CLC bio, Aarhus, Denmark) as described in [Online Methods in Supplementary Material](#SD1){ref-type="supplementary-material"}. Mutation calling was performed in parallel with a team of geneticists/cell biologists, who had knowledge of the clinical phenotypes and pedigree structure, as well as experience with homozygosity mapping and exome evaluation. Because exon capture with subsequent massively parallel sequencing yields too many variants from normal reference sequence (VRSs) to make a confident decision regarding the disease-causing mutation of a single recessive disease-causing gene^[@R18],\ [@R25]^, we devised a strategy of *a priori* reduction of VRSs (see [Online Methods](#SD1){ref-type="supplementary-material"} ('Filtering of variants from normal reference sequence') and [Table S1 in Supplementary Material](#SD1){ref-type="supplementary-material"}).^[@R18]^

Supplementary Material {#SM}
======================
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![Images of representative renal ultrasound (RUS) and renal biopsy findings in individuals with an initial diagnosis of "NPHP-RC"\
(**a**) In A2557-21 with a mutation in *NPHP4*, RUS showed a normal-sized kidney with increased echogenicity when compared to liver (L), corticomedullary cysts (CMC) and loss of corticomedullary differentiation (CMD).\
(**b**) In F93-29 with homozygosity mapping implicating the *PKHD1* locus, RUS showed normal sized kidneys with small CMC and diminished CMD.\
(**c**) In both siblings, F650-21 (left panel) and F650-22 (right panel) with dRTA as indicated by a mutation in *SLC4A1*, RUS exhibits increased echogenicity and CMC in normal sized kidneys with loss of CMD, which prompted the diagnosis of NPHP-RC early in the course of disease.\
(**d**) In A3254 (left panel) and A3255 (right panel) with the molecular diagnosis of hyperoxaluria type 1 as indicated by a mutation in *AGXT*, RUS of A3255 exhibited CMC. RUS of A3254 showed mild distention of the collecting ducts.\
(**e**) Right kidneys of siblings F838-21 (left panel) and -22 (right panel) harboring a heterozygous mutation in *INPP5E* exhibited CMC and increased echogenicity comparable to liver (L) signal.](nihms533710f1){#F1}

![Recessive mutations detected by WER in 10 sibling cases with an NPHP-RC phenotype\
Families are listed in the same order as in [Table 1](#T1){ref-type="table"}. Family numbers (underlined), *mutated gene*, altered nucleotides and amino acid changes are given above sequence traces. Wild type control sequences are shown below mutated sequences. Codon triplets are underlined to indicate reading frame. Non-coding sequence is in lower case. Mutated nucleotides are denoted by an arrow head. All mutations were absent from \>270 ethnically matched healthy controls. Five families have mutations in the known ciliopathy genes *INVS/NPHP2*, *NPHP4*, *BBS1*, *BBS9*, and *ALMS1*. Two families have mutations in known NPHP-RC phenocopying genes (*SLC4A1* and *AGXT*). In F838 a heterozygous mutation was detected in *INPP5E*.](nihms533710f2){#F2}

###### Primay causal mutations and clinical phenotypes of 10 sibships with diagnosis of a "nephronophthisis-related ciliopathy"

Highlights denote known NPHP-RC genes (blue) and known NPHP-RC phenocopying genes (red).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family\                                                   Ethnic\         Causative\                        Nucleotide\                                                                 Deduced\                                   Exon\                                     Continuous\         Parental\             Kidney\                                                                                   Eye\                             Other
  -Individual[a](#TFN1){ref-type="table-fn"}                origin          Gene                              alteration[b](#TFN2){ref-type="table-fn"},[c](#TFN3){ref-type="table-fn"}   protein\                                   (state)                                   amino acid\         consanguinity         (age at ESKD)                                                                             (age at RD)                      
                                                                                                                                                                                          change                                                                               sequence\                                                                                                                                                            
                                                                                                                                                                                                                                                                               conservation\                                                                                                                                                        
                                                                                                                                                                                                                                                                               in\                                                                                                                                                                  
                                                                                                                                                                                                                                                                               evolution                                                                                                                                                            
  --------------------------------------------------------- --------------- --------------------------------- --------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------- ------------------- --------------------- ----------------------------------------------------------------------------------------- -------------------------------- -------------------------------------------------------------------------------------------
  [**Mutation of known *NPHP-RC* genes**]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                      

  **A2204**\                                                Arab            ***INVS/NPHP2***                  c.2719C\>T[d](#TFN4){ref-type="table-fn"}                                   p.R907X                                    13 (Hom)                                  \-                  Yes                   \                                                                                         nl                               \-
    −21\                                                                                                                                                                                                                                                                                                                 −21: (4 yr)\                                                                                                               
    −23                                                                                                                                                                                                                                                                                                                  −23: (4 yr?)                                                                                                               

  **A2557**\                                                Arab African    ***NPHP4***                       c.402delG                                                                   p.I135SfsX43                               4 (Hom)                                   \-                  Yes                   [Bx]{.ul}: NPHP\                                                                          nl                               polyuria, failure to thrive, salt craving
    −[21]{.ul}\                                                                                                                                                                                                                                                                                                          −11: died 13 yr\                                                                                                           
    −31 (cousin)                                                                                                                                                                                                                                                                                                         −21: (at 9 yr, Creat. 7 mg/dL) ([Figure 1a](#F1){ref-type="fig"})\                                                         
                                                                                                                                                                                                                                                                                                                         −31: (at 32 yr Creat. 7 mg/dL)\                                                                                            
                                                                                                                                                                                                                                                                                                                         [RUS]{.ul}: echogenic kidneys, CMC                                                                                         

  **A2882 (KK7)**\                                          Saudi Arabian   ***BBS1***                        c.1062 +58C\>T[d](#TFN4){ref-type="table-fn"}                               cryptic splice site activation             Intron 10 (Hom)                           \-                  Yes                   \                                                                                         Retinitis pigmentosa             −21, −22: BBS, postaxial polydactyly, obesity\
    −21 (03)\                                                                                                                                                                                                                                                                                                            −21: ND\                                                                                                                   −21: webbed thumbs\
    −[22]{.ul} (04)                                                                                                                                                                                                                                                                                                      −22: nl                                                                                                                    −22: speech delay

  **A2888 (R1)**\                                           Latino          ***BBS9***                        c.1536A\>G                                                                  p.T512T, 60% conserved splice donor site   14 (Hom)                                  \-                  Yes                   \                                                                                         Retinitis pigmentosa             BBS
  −21 (04)\                                                                                                                                                                                                                                                                                                              −21: ND\                                                                                                                   
  −[22 (05)]{.ul}                                                                                                                                                                                                                                                                                                        −22: ND                                                                                                                    

  **A2841 (AR245)**\                                        Europe          ***ALMS1***                       c.5900C\>G\                                                                 p.S1967X\                                  7 (het)\                                  \-                  No                    −21: left and right kidney enlargement\                                                   Nystagmus\                       −21, −22: Alström syndreome, obesity, insulin resistance, cardiomyopathy\
    −[21 (03)]{.ul}\                                                                                          c.8383insA                                                                  p.L2797fsX3                                9 (het)                                                                             −22: kidney enlargement                                                                   Retinitis pigmentosa             −21: recurrent otitis media, developmental delaly\
    −[22 (04)]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                                                 −22: microcephaly, asthma

  [**Mutation of known NPHP-RC-phenocopying genes**]{.ul}                                                                                                                                                                                                                                                                                                                                                                                           

  **F650**\                                                 Turkey          ***SLC4A1***                      c.1571--1573delTCT                                                          p.delF524                                  13 (Hom)                                  *C. elegans*        Yes (1^st^ cousins)   −21, −22:\                                                                                −21: coloboma of iris, choroid   −21, −22: polyuria, failure to thrive, blood pH \<7.35, oral intake of NaHCO~3~, 3 g /day
    −[21]{.ul}\                                                                                                                                                                                                                                                                                                          [Bx at 19 yr, 18 yr]{.ul}:\                                                                                                
    −22                                                                                                                                                                                                                                                                                                                  NPHP (global sclerosis, cystic ectasia)\                                                                                   
                                                                                                                                                                                                                                                                                                                         [RUS at 35 yr, 34 yr]{.ul}: ↑ EG, CMC, nl size ([Figure 1c](#F1){ref-type="fig"})                                          

  [**A3254**]{.ul}\                                         Saudi Arabia    ***AGXT***                        c.584T\>G[d](#TFN4){ref-type="table-fn"}                                    p.M195R                                    5 (Hom)                                   *D. melanogaster*   Yes                   A3254: (ESKD stage 5)\                                                                    A3254: retinal pigmentation\     A3254: brain atrophy, developmental delay; hypotonia\
  **A3255** (cousins)                                                                                                                                                                                                                                                                                                    [RUS]{.ul}: A3254: ↑ EG, nl size, mild distention of the collecting system\               \                                \
                                                                                                                                                                                                                                                                                                                         A3255 (3 mo): ↑ EG, echogenic kidneys, died at 19 mo ([Figure 1d](#F1){ref-type="fig"})   A3255: retinal pigmentation      A3255: brain atrophy (MRI), short stature, CHD, respiratory failure, bone disease

  [**Genetically unsolved cases**]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                             

  **F93** (A3223)\                                          Germany         [e](#TFN5){ref-type="table-fn"}   ND[e](#TFN5){ref-type="table-fn"}                                           ND[e](#TFN5){ref-type="table-fn"}          ND (Hom)[e](#TFN5){ref-type="table-fn"}   \-                  Yes                   [Bx]{.ul} (−21, −24, −25):\                                                               \                                \
  \                                                                                                                                                                                                                                                                                                                      NPHP\                                                                                     \                                \
    −21\                                                                                                                                                                                                                                                                                                                 −21: (15 yr)\                                                                             \                                \
    −24\                                                                                                                                                                                                                                                                                                                 −24: (10 yr)\                                                                             −24:coloboma                     −24: thorax deformity
    −[25]{.ul}\                                                                                                                                                                                                                                                                                                          −25: (died 5 yr)\                                                                                                          
    −[29]{.ul}                                                                                                                                                                                                                                                                                                           −29: (14 yr)\                                                                                                              
                                                                                                                                                                                                                                                                                                                         [RUS (−24, −29)]{.ul}: small kidneys, CMC ([Figure 1b](#F1){ref-type="fig"})                                               

  **F838**\                                                 Poland          ***INPP5E***                      c.925C\>T                                                                   p.Q309X                                    (het)                                     \-                  No                    Bx: NPHP\                                                                                 nl                               \-
    −[21]{.ul}\                                                                                                                                                                                                                                                                                                          −21: (6 yr)\                                                                                                               
    −22                                                                                                                                                                                                                                                                                                                  −22: (7 yr)\                                                                                                               
                                                                                                                                                                                                                                                                                                                         [RUS]{.ul}: echogenic kidneys, CMC ([Figure 1e](#F1){ref-type="fig"})                                                      

  **A2059**\                                                Turkey          \-                                \-                                                                          \-                                         \-                                        \-                  Yes                   \                                                                                         nl                               \
    −[21]{.ul}\                                                                                                                                                                                                                                                                                                          −21: (at 25 yr Creat. 1.0 mg/dL)\                                                                                          \
    −22\                                                                                                                                                                                                                                                                                                                 \                                                                                                                          \
    −23                                                                                                                                                                                                                                                                                                                  −23: (at 19 yr Creat. 7.8 mg/dL)\                                                                                          −23: heart anomaly
                                                                                                                                                                                                                                                                                                                         RUS: small kidneys                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Individual with exome sequencing data is underlined in first column.

For GenBank accession numbers see [Online Methods in Supplementary Material](#SD1){ref-type="supplementary-material"})

All mutations were absent from \>270 healthy control individuals.

Mutation published in BIOBASE (<http://www.biobase-international.com>).

Although no mutation was detected, linkage mapping excluded all loci but the *PKHD1* locus (see [Figure S1h](#SD1){ref-type="supplementary-material"}).

BBS, Bardet-Biedl syndrome; Bx, Kidney biopsy demonstrates nephronophthisis; CHD, congenital heart defect; CMC, corticomedullary cysts; Creat., serum creatinine; EG, echogenicity; ERG, electroretinogram; ESKD, end-stage kidney disease; GFR, glomerular filtration rate; Hom, homozygous mutation; het, heterozygous mutation; mo, months; ND no data; nl, normal; RD, retinal degeneration; RUS, renal ultrasound; yr, year(s); -, not applicable.

[^1]: These authors contributed equally to this work.
